GGrantIndex
← Leaderboards

David R Karp

Yeshiva University

Google Scholar ↗PubMed ↗ORCID ↗
$9,612,358
Attributed
$16,008,754
Total exposure
9
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,479,545 · 10

By mechanism

U01$10,810,801 · 2
P50$2,211,138 · 2
R01$2,061,946 · 2
RC1$974,414 · 1
U34$682,773 · 1
P01$426,473 · 1

Top collaborators

Others in their field

Top investigators on “Lupus”

Research focus

LupusResearch PersonnelEnrollmentLaboratoriesAutoimmune DiseasesSystemic Lupus ErythematosusCytokineLupus ErythematosusOrganDouble-Blind MethodPopulations At RiskHydroxychloroquinePreventClinical TrialsClassificationDiagnosisProtocols DocumentationResourcesSamplingPharmaceutical PreparationsAutoantibodiesBiological MarkersPlasmaEarly Diagnosis

Grant awards (31)

Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)$1,252,131
U01 · FY2025 · AI · contact PI
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)$1,258,259
U01 · FY2024 · AI · contact PI
Supplement to Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)$216,290
U01 · FY2024 · AI · contact PI
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)$1,291,119
U01 · FY2023 · AI · contact PI
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$934,842
U01 · FY2022 · AR
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,315,081
U01 · FY2021 · AR
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,649,605
U01 · FY2019 · AR
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,449,776
U01 · FY2018 · AR
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,443,698
U01 · FY2017 · AR
Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus$321,048
U34 · FY2016 · AR
Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus$361,725
U34 · FY2015 · AR
NIAMS: CORT - Genetic Dissection of SLE--From Mouse to Man$1,470,791
P50 · FY2011 · AR · contact PI
Clinical Resource Core$131,410
P50 · FY2011 · AR · contact PI
High Throughput Screening of the Autoimmune Epitome$485,635
RC1 · FY2010 · AR · contact PI
Clinical Resource Core$161,163
P50 · FY2010 · AR · contact PI
High Throughput Screening of the Autoimmune Epitome$488,779
RC1 · FY2009 · AR · contact PI
Clinical Resource Core$143,076
P50 · FY2009 · AR · contact PI
Clinical Resource Core$174,785
P50 · FY2008 · AR · contact PI
Clinical Resource Core$129,913
P50 · FY2007 · AR · contact PI
Oxidative Stress and Functional Lymphocyte Development$266,585
R01 · FY2006 · AI · contact PI
Oxidative Stress and Functional Lymphocyte Development$273,000
R01 · FY2005 · AI
The Function of Human AIM in Rheumatic Disease$156,000
R21 · FY2005 · AR
Oxidative Stress and Functional Lymphocyte Development$273,000
R01 · FY2004 · AI
The Function of Human AIM in Rheumatic Disease$156,000
R21 · FY2004 · AR
Oxidative Stress and Functional Lymphocyte Development$273,000
R01 · FY2003 · AI
Oxidative Stress and Functional Lymphocyte Development$273,000
R01 · FY2002 · AI
GAMMA GLUTAMYL TRANSPEPTIDASE &LYMPHOCYTE ACTIVATION$241,419
R01 · FY2002 · AI
CORE--PROTEIN AND MOLECULAR BIOLOGY FACILITY$247,465
P01 · FY2001 · AI
GAMMA GLUTAMYL TRANSPEPTIDASE &LYMPHOCYTE ACTIVATION$234,385
R01 · FY2001 · AI
GAMMA GLUTAMYL TRANSPEPTIDASE &LYMPHOCYTE ACTIVATION$227,557
R01 · FY2000 · AI
CORE--PROTEIN AND MOLECULAR BIOLOGY FACILITY$179,008
P01 · FY2000 · AI